Chinese FDA Fast Tracks Approval For D-Pharm’s Epilepsy Drug

June 9, 2014 | The Israeli biopharmaceutical company D-Pharm‘s anti-epileptic drug DP-VPA is set to be fast tracked for approval by the Chinese Food and Drug Administration (CFDA). The drug, which has been deemed a novel treatment by healthcare professionals, is derived from the generic drug valproic acid that is used for the treatment of epilepsy, migraine headaches and bipolar disorder. The DP-VPA treatment for epilepsy has already completed a Phase II clinical trial, and with CFDA approval, D-Pharm will develop the drug together with its local Chinese partner Jiangsu NHWA Pharmaceutical Company. D-Pharm was founded in 1993 in the Kiryat Weizmann Science Park in Rehovot and focuses on the development of innovative drugs for the treatment of central nervous system disorders.